INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02977780 |
Recruitment Status :
Recruiting
First Posted : November 30, 2016
Last Update Posted : August 9, 2023
|
Sponsor:
Patrick Wen, MD
Collaborators:
Eli Lilly and Company
Celgene
Puma Biotechnology, Inc.
Accelerate Brain Cancer Cure
Quadriga Biosciences, Inc.
Information provided by (Responsible Party):
Patrick Wen, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | March 1, 2025 |
Estimated Study Completion Date : | December 31, 2025 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):